

## Therapeutic Use Exemption (TUE) Beta-2 Agonist Application Form



TUE applications for the use of formoterol and terbutaline require a medical file to confirm the diagnosis of asthma and/or its clinical variants. The medical file should include:

- A detailed medical history and clinical review
- Bronchodilator or Bronchoprovocation test results

For further information on how to submit a complete medical file use the diagnostic flow chart on page 2 of this application form.

Please complete **all** sections in **BLOCK CAPITALS**. **Incomplete** or **illegible** forms will be returned.

### Athlete Information

Surname: \_\_\_\_\_ First names: \_\_\_\_\_

Date of Birth (dd/mm/yy):   /   /   Gender: Male  Female  (please tick)

Address: \_\_\_\_\_

\_\_\_\_\_ Postcode     -

Contact Tel. (including dialling code)

E-mail: \_\_\_\_\_

Sport: \_\_\_\_\_ Club: \_\_\_\_\_

(indicate the discipline if appropriate)

National Governing Body: \_\_\_\_\_ Disability category: \_\_\_\_\_

Level of competition: (please tick one box as appropriate)

I am part of my International Federation's Registered Testing Pool

I am competing in an International event

I am part of UK Anti-Doping's National Registered Testing Pool

I am competing in a National Level event in my sport

Other  (please state level) \_\_\_\_\_

Next competition the Therapeutic Use Exemption is required for:  
\_\_\_\_\_

Competition date (dd/mm/yy):   /   /


(a) Have you submitted a previous TUE application? Yes  No

(b) The Anti-Doping Organisation applied to? UK Anti-Doping  Other  \_\_\_\_\_ (please state)

(c) Decision: Approved  Declined

## Medical File Requirements

The diagnostic flow chart below provides an outline of how to submit a complete medical file to UK Anti-Doping to confirm the diagnosis of asthma and/or its clinical variants.



**\*NB.** It is recommended that a bronchodilator challenge is the investigation of preference in athlete's with abnormal resting lung function ( $FEV_1 < 70\%$  predicted at baseline,  $FEV_1/FVC < 0.7$ ); a bronchodilator challenge should be considered if  $FEV_1$  is 70-80% predicted at baseline; a bronchodilator challenge is still an option but a bronchoprovocation challenge might be more suitable when  $FEV_1 > 80\%$  predicted at baseline.

## Medical History Report and Medication Details

(a) Diagnosis (i.e. asthma, exercise induced asthma, exercise induced bronchoconstriction):

(b) Age of onset:

-----

(c) Symptoms experienced: (Please tick as appropriate)

Recurrent breathlessness       Coughing       Wheezing   
 Difficulty in breathing (Dyspnoea)       Excess mucus production       Chest tightness

Please specify: -----

(d) When are these symptoms experienced?

(e) What environmental conditions trigger the above symptoms? (Please tick as appropriate)

Cold climate       Dry air       High pollen count   
 Air pollution       Altitude training       Other

If other, please state -----

(f) List all asthma medication used in the last 3 months (e.g. beclomethasone, mometasone, salbutamol):

(g) Has the athlete any history of atopic disorders and/or childhood asthma?

(h) Provide details of any acute exacerbations of asthma including hospital emergency department attendance/admission reports and/or previous treatment with oral corticosteroids (please attach documents to confirm these details):

(i) Asthma medication details:

Generic name of Prohibited Substance(s)	Dose of administration	Route of administration	Frequency of administration	Maximum dosage permitted within 24 hrs
1.	µg	Inhaled		µg
2.	µg	Inhaled		µg
3.	µg	Inhaled		µg
4.	µg	Inhaled		µg

Intended duration of treatment(s): Emergency       Weeks/Months       Please specify:

## Notifying Medical Practitioner Details and Declaration

Name: \_\_\_\_\_

Qualifications: \_\_\_\_\_

Medical speciality: \_\_\_\_\_

Contact Tel.

Practice stamp/address

E-mail: \_\_\_\_\_

I certify the above-mentioned substance(s) for the above named athlete has been/are to be administered as the correct treatment for the above named medical condition. I further certify that the use of alternative medications not on the Prohibited List would be unsatisfactory for the treatment of the above named medical condition.

If the athlete is under 18 and I have not notified the athlete's parent/guardian, this is because I consider the athlete to be competent to give consent to treatment.

I understand that my details will be held on an anti-doping database and will be accessible by the Athlete, their National Governing Body, their International Federation, UK Anti-Doping, and the World Anti-Doping Agency in order to allow them to administer the anti-doping programme.

**Signature of medical practitioner:** \_\_\_\_\_

**Date:**   /   /

If the athlete is under 18 does the athlete's parent/guardian know about this treatment? Yes  No

## Clinical Examination

Clinical examination findings with specific focus on the respiratory system were: Normal  Abnormal

**Specify any abnormal examination findings in this box:**

## Baseline Spirometry

Date:   /   /   Best Baseline FEV<sub>1</sub>: \_\_\_\_\_ L (must be within 5% of second best FEV<sub>1</sub>)

**NB.** The application will not be reviewed unless the data for at least two flow loops are presented in the table below and that the best baseline FEV<sub>1</sub> is within 5% of the second best FEV<sub>1</sub>. Further flow loops are required if the best baseline FEV<sub>1</sub> value is not within 5% of second best FEV<sub>1</sub> value at baseline.

	FEV <sub>1</sub> (L)	FVC (L)	FEV <sub>1</sub> /FVC (%)	FEF <sub>25-75</sub> (L·s <sup>-1</sup> )
1 <sup>st</sup> Flow Loop				
% Predicted				
2 <sup>nd</sup> Flow Loop				
% Predicted				
3 <sup>rd</sup> Flow Loop				

**Abbreviations:** **FEV<sub>1</sub>**, Forced Expiratory Volume in one second; **FVC**, Forced Vital Capacity; **FEF<sub>25-75</sub>**, Forced Expiratory Flow between 25-75% of vital capacity; **L**, Litres; **L·s<sup>-1</sup>**, Litres per second.

## Bronchodilator Challenge

If chosen as the test to confirm asthma, please complete this section and attach an electronic printout of test results if available.

**NB.** The application will not be reviewed unless duplicate FEV<sub>1</sub> measurements are presented in the table below. Duplicate FEV<sub>1</sub> values must also agree within 5% & 150ml of each other to confirm reproducibility of the best FEV<sub>1</sub> value measured.

Date of challenge: // Bronchodilator & dose used: \_\_\_\_\_

Time post-test	FEV <sub>1</sub> Post BD dose (L)		% difference from baseline FEV <sub>1</sub> (using best of duplicate)	FVC Post BD dose (L)		% difference from baseline FVC (using best of duplicate)
	Duplicate 1	Duplicate 2		Duplicate 1	Duplicate 2	
min						
min						

Technician Name & Contact details: \_\_\_\_\_

Comments (optional):

## Bronchoprovocation Challenge

If chosen as the test to confirm asthma, please provide a summary of the test results below & attach either:

- Electronic printout of spirometry results and flow volume loop tracing; or
- A bronchoprovocation data collection worksheet (**NB.** Worksheets can be found on the UK Anti-Doping website if the centre completing the bronchoprovocation challenge does not have their own).

**NB.** The application will not be reviewed unless duplicate FEV<sub>1</sub> measurements are taken at each time point.

EVH – Fall in FEV<sub>1</sub> at two consecutive time points:

Time point 1: \_\_\_\_\_ min      Best FEV<sub>1</sub> value at time point: \_\_\_\_\_ L      FEV<sub>1</sub> fall from baseline: \_\_\_\_\_ %

Time point 2: \_\_\_\_\_ min      Best FEV<sub>1</sub> value at time point: \_\_\_\_\_ L      FEV<sub>1</sub> fall from baseline: \_\_\_\_\_ %

Exercise – Fall in FEV<sub>1</sub> at two consecutive time points:

Time point 1: \_\_\_\_\_ min      Best FEV<sub>1</sub> value at time point: \_\_\_\_\_ L      FEV<sub>1</sub> fall from baseline: \_\_\_\_\_ %

Time point 2: \_\_\_\_\_ min      Best FEV<sub>1</sub> value at time point: \_\_\_\_\_ L      FEV<sub>1</sub> fall from baseline: \_\_\_\_\_ %

Mannitol – True baseline FEV<sub>1</sub> following 0mg mannitol dose: \_\_\_\_\_ L

PD15: \_\_\_\_\_ mg      FEV<sub>1</sub> value at dose that induced a > or = 15% fall: \_\_\_\_\_ L      FEV<sub>1</sub> fall from true baseline: \_\_\_\_\_ %

FEV<sub>1</sub> value at dose prior to 15% fall: \_\_\_\_\_ L      Dose: \_\_\_\_\_ mg      FEV<sub>1</sub> fall from true baseline: \_\_\_\_\_ %

A 10% incremental fall in FEV<sub>1</sub> between doses: \_\_\_\_\_ mg (dose 1) and \_\_\_\_\_ mg (dose 2)

FEV<sub>1</sub> fall from true baseline at dose 1 \_\_\_\_\_ L \_\_\_\_\_ % and FEV<sub>1</sub> fall from true baseline at dose 2 \_\_\_\_\_ L \_\_\_\_\_ %

Date of challenge: // Comments (optional):

Technician Name & Contact details: \_\_\_\_\_

## Athlete's Declaration

I certify that the information under Section 1 of this TUE application form is accurate and that I am requesting approval to use a substance or method on the World Anti-Doping Code (WADC) Prohibited List.

I authorise the release of personal medical information related to this application to the National Anti-Doping Organisation (NADO, namely UK Anti-Doping) as well as to World Anti-Doping Agency (WADA) staff, to the NADO's Therapeutic Use Exemption Committee (TUEC) and to other Anti-Doping Organisations (ADO) under the provisions of the WADC and the anti-doping rules of my sport.

I understand and agree that:

- My TUE data will only be used to allow the above organisations to administer the anti-doping programme in accordance with the WADC International Standard for TUEs;
- My TUE data will be collected by the NADO who shall be principally responsible for ensuring the protection of this data. The NADO will use the Anti-Doping Administration and Management System (ADAMS) to store, process and manage my data, including its disclosure to authorised recipients;
- My TUE data, or part of it, will be made accessible to authorised ADOs (for instance, designated NADOs, the International or National Federation of my Sport, and WADA);
- My TUE data may have to be shared with other independent medical and/or scientific experts, and all necessary staff involved in the management, review or appeals of TUEs if applicable;
- Persons or parties receiving my information may be located outside the country where I reside. In some other countries data protection and privacy laws may not be equivalent to those in my own country;
- I may have certain rights under applicable laws in relation to my TUE data, including rights to access and/or correct any inaccurate data; and
- To the extent that I have any concerns about the processing of my TUE data I may consult with the NADO and/or WADA as appropriate.

### Withdrawal of Consent

I understand that if I ever wish to revoke the right of the NADO & authorised ADOs (designated NADOs, the International or National Federation of my Sport, and WADA) to access my TUE information, I must notify my medical practitioner and the NADO in writing of that fact.

### Authorisation and Consent

By signing this form I expressly consent to the use of my TUE data as set out above.

**Athlete's signature:** \_\_\_\_\_

**Date:** / /

**Parent/guardian signature** \_\_\_\_\_

**Date:** / /

*(If the athlete is under 18 and is not deemed to be competent to give their consent to the treatment or has a disability preventing him/her to sign this form, a parent or guardian shall sign together with or on behalf of the athlete).*

I would like the decision to be sent to: (please tick one box as appropriate)

My postal address

My e-mail address

The notifying medical practitioner

---

MARK AS CONFIDENTIAL AND PLEASE SUBMIT THE COMPLETED FORM TO UK ANTI-DOPING AND KEEP A COPY FOR YOUR RECORD:

**TUE**  
**UK Anti-Doping**  
**Oceanic House, 1a Cockspur Street, London, SW1Y 5BG**  
Confidential fax: **0800 298 3362** / e-mail: [tue@ukad.org.uk](mailto:tue@ukad.org.uk)